Skip to main content
Fig. 1 | BMC Pharmacology and Toxicology

Fig. 1

From: Assessment of safety and tolerability of remogliflozin etabonate (GSK189075) when administered with total daily dose of 2000 mg of metformin

Fig. 1

Summary Schematic of Study Design. Dosing of Cohort 2 commenced after at least 18 subjects in Cohort 1 had completed dosing and preliminary safety information had been reviewed. Two subjects were withdrawn; one for mild supraventricular tachycardia and one lost to follow-up. BID = twice daily; Met = metformin; RE = Remogliflozin etabonate

Back to article page

BMC Pharmacology and Toxicology

ISSN: 2050-6511

Contact us